E229: From Reactive to Proactive: What a QP's Job Should Actually Look Like in 2026

<p>In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Jitesh Halai, founder and CEO of OneSC, about what the Qualified Person role should look like in a more proactive, digitally connected pharmaceutical supply chain.</p><p>Jitesh explains how many QPs are still forced into reactive work: chasing documents, checking versions, searching inboxes, reconciling batch data across disconnected systems and trying to work out what is holding up release. In virtual pharma environments, where much of the supply chain is outsourced, that burden becomes even heavier.</p><p>The conversation explores how platforms like OneSC can create a single source of truth across supply chain partners, giving QPs live visibility of batch status, documentation, review progress and quality signals. Instead of waiting weeks for all documents to arrive before spotting a packaging, leaflet or batch data issue, automated checks can flag risks much earlier.</p><p>Jitesh also discusses how AI, OCR and automation can reduce repetitive administrative work, without replacing human judgement. The aim is not to remove the QP from the process, but to give them more time for the work they were trained to do: critical review, risk assessment and patient safety decisions.</p><p>The key message is clear: the future QP should not be fighting their mailbox. They should have consolidated batch information, automated signals and the confidence to move from reactive release management to proactive quality oversight.</p><p>Topics Covered</p><ul><li><p>Why QPs are stuck in reactive work</p></li><li><p>Batch review, release and document chasing</p></li><li><p>The burden of disconnected systems</p></li><li><p>Creating a single source of truth</p></li><li><p>Automated checks for earlier risk detection</p></li><li><p>AI, OCR and automation in quality workflows</p></li><li><p>Reducing cognitive burden for QPs</p></li><li><p>Why human judgement still matters</p></li><li><p>How real-time auditing may evolve</p></li></ul><p>Eularis helps pharma and biotech leaders turn AI activity into board-defensible governed strategy and measurable commercial outcomes.</p><p>If your CFO asked tomorrow for the projected return of each major AI initiative - by year, across three years, with explicit adoption, operating cost and redeployment assumptions - could you produce an answer that survives scrutiny?</p><p>And if you could: would you know which of those initiatives most moves the company toward the outcomes i